January 11, 2026 a 09:00 pm
AMGN: Analysts Ratings - Amgen Inc.
Amgen Inc., a leading biopharmaceutical company, continues to capture the interest of analysts with its innovative product portfolio. With a robust pipeline focused on several critical therapeutic areas, Amgen's market position is seen as stable. However, the Sentiment analysis indicates a mix of cautious optimism and cautious holds, reflecting both opportunities and ongoing market challenges.
Historical Stock Grades
| Rating Type | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 11 | |
| Hold | 15 | |
| Sell | 2 | |
| Strong Sell | 1 |
Sentiment Development
Over the past months, there has been a notable shift in analyst sentiment regarding Amgen Inc. The number of "Buy" recommendations has slightly increased, while "Strong Buy" ratings experienced a small decline. This fluctuation suggests a more cautious sentiment among analysts, possibly due to market conditions or company-specific developments.
- The total number of ratings has shown slight growth, indicating sustained analyst interest.
- "Strong Buy" recommendations have decreased from 6 to 4 over the past year.
- "Hold" ratings have remained stable, highlighting a conservative outlook among analysts.
Percentage Trends
Recent data illustrates a shift in the distribution of Amgen Inc.'s analyst ratings. The percentage of "Strong Buy" ratings has gradually decreased, as "Hold" and "Buy" ratings maintain a steady presence. This trend may point to growing caution amidst uncertain market conditions.
- As of January 2026, "Strong Buy" constitutes 11% of total recommendations, down from 17% in mid-2025.
- "Buy" ratings have oscillated between 28% and 31% over the last year.
- "Hold" ratings consistently represent about 42% of recommendations, supporting the cautious sentiment.
- Changes over the past year suggest an increased reticence among analysts, with fewer aggressive buying signals.
Latest Analyst Recommendations
Reviewing the latest analyst recommendations for Amgen Inc., it becomes evident that there is a consistent "Hold" and "Equal Weight" sentiment. These steady evaluations reflect a conservative approach as analysts monitor future developments.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-08 | Hold | Hold | Truist Securities |
| 2025-12-12 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-12-10 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-12-03 | Outperform | Outperform | BMO Capital |
| 2025-11-14 | Overweight | Overweight | Piper Sandler |
Analyst Recommendations with Change of Opinion
Examining recent changes in analyst recommendations uncovers a trend of downgrades in sentiment. Downgrades from "Buy" to "Hold" and from "Overweight" to "Equal Weight" highlight growing caution, while a few upgrades signal occasional renewed confidence.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2024-10-14 | Hold | Buy | Truist Securities |
| 2024-08-07 | Equal Weight | Overweight | Wells Fargo |
| 2024-05-03 | Equal Weight | Underweight | Barclays |
| 2024-05-03 | Outperform | Market Perform | William Blair |
| 2023-12-21 | Buy | Neutral | Daiwa Capital |
Interpretation
The data suggests a cautious stance among analysts towards Amgen Inc., with many opting for "Hold" or similar neutral ratings. Downgrades reflect wary sentiment amidst potential market challenges, though occasional upgrades highlight underlying confidence in the company's core strengths. While some uncertainty lingers, the overall sentiment maintains stability, indicating that analysts are awaiting further developments before altering their positions significantly.
Conclusion
In conclusion, Amgen Inc.'s stock has experienced fluctuating analyst sentiment, with a noticeable shift towards more conservative ratings over the past year. The balance between caution and confidence reflects Amgen's solid market position, offset by market uncertainties. Analysts appear watchful, with slight but meaningful shifts in outlook signaling a wait-and-see approach. The company's diversified portfolio and strategic partnerships remain key strengths, although the analyst community seeks more definitive catalysts before embracing a robust bullish outlook.